1.Analysis and prediction of disease burden of stroke and its subtypes in China from 1990 to 2040.
Jing WANG ; Chunlong XIAO ; Zhao CHENG ; Hongxiang LIU ; Weixi ZHANG ; Chuanhua YU
Chinese Medical Journal 2025;138(19):2452-2463
BACKGROUND:
In China, stroke burden remains severe as it is a major cause of mortality and disability. Detailed analyses across different subtypes will help optimize intervention strategies, enhance resource allocation efficiency, and ultimately reduce the overall disease burden.
METHODS:
We conducted a descriptive analysis of the incidence, prevalence, mortality, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) of stroke and its subtypes using data (1990-2021) from the Global Burden of Disease (GBD) database. A Joinpoint regression model was applied to quantitatively analyze the indicators and calculate the annual percentage change (APC) and average annual percentage change (AAPC). We applied the Bayesian age-period-cohort (BAPC) model to project trends for 2022-2040.
RESULTS:
Incidence of stroke increased by 100.64% from 1990 to 2021, with ischemic stroke (IS) exhibiting the largest increase (201.13%) among all the subtypes, and the incidence being consistently higher in males than in females. The YLL/YLD ratio for stroke and its subtypes has decreased, with the YLL/YLD ratio falling from 20.13 to 9.48 in 1990-2021, indicating an increase in non-fatal burden. After adjusting for age, the age-standardized incidence rates (ASIRs) of stroke and its subtypes declined, except for IS. The age-standardized mortality rate (ASMR) for subarachnoid hemorrhage (SAH) decreased significantly (APC: -15.31%; 2000-2004), with the largest reduction in the age-standardized DALY rate (ASDR) also occurring during this period (APC: -14.22%). Furthermore, BAPC projections (2022-2040) indicate that stroke ASIRs in males will slightly decline but increase in females. Meanwhile, the ASIR of IS is expected to continue to rise. Overall, the ASMR and ASDR are projected to decline.
CONCLUSIONS
Although China has made some progress in stroke prevention and control, several challenges remain. Controlling IS must be prioritized, especially due to the high stroke burden among males.
2.Trend and age-period-cohort analysis of heart disease deaths and DALY attributable to high-salt diets in Chinese residents in 1990 -2019
Journal of Public Health and Preventive Medicine 2024;35(3):1-5
Objective To understand the trends of the mortality and DALY of ischemic heart disease (IHD) caused by high-salt diets,as well as their age-period-cohort effects among Chinese residents from 1990 to 2019. Methods Using the 2019 Global Burden of Disease Study (GBD 2019) data on IHD deaths and DALY attributed to high-salt diets among Chinese residents from 1990 to 2019, an age-period-cohort (APC) model was applied to explore the age-period-cohort effect. Results Among the 13 major risk factors for ischemic heart disease (IHD) in China in 1990 and 2019, age-standardized mortality and age-standardized DALY rates attributable to risk factors of high-salt diets led the way. Age-standardized mortality and age-standardized DALY rates were attributabled to high-salt diets showed a decreasing trend in both China and globally in 1990-2019, but were consistently higher in China than in the world. The results of the APC model show that from 1990 to 2019, the mortality rate and DALY rate of IHD attributed to a high-salt diet in China showed an increasing trend with age; over time, the risk of death and the risk of DALY for males showed a decreasing trend from 1990-1994 to 1995-1999, and an increasing trend from 1995-1999 to 2010-2014, and reached its peak in 2010-2014 (RR=1.17,95% CI: 1.12-1.21), followed by a decreasing trend. For males with a later birth cohort have a higher risk of death and DALY, while for females with a later birth cohort have a lower risk of death and DALY. Conclusion The burden of IHD disease attributed to a high-salt diet in China is still relatively heavy, and it is necessary to strengthen protection for high-risk populations such as young males and the elderly population to reduce the burden of IHD disease in China.
3.Determination of Cyperenone and α-Cyperone in Rat Plasma by UPLC-MS/MS and Their Pharmacokinetics
Chuanhua FENG ; Huiling GUO ; Xiaolin TANG ; Xiaojuan ZHAO ; Xinlu FAN ; Dekun LIU ; Gang LI
Chinese Journal of Modern Applied Pharmacy 2023;40(23):3197-3201
OBJECTIVE To establish an UPLC-MS/MS method for the determination of the concentrations of cyperenone and α-cyperone in rat plasma and to study the pharmacokinetics. METHODS Gradient elution was carried out on a Phenomennex C18(150 mm×2.0 mm, 3 μm) column with acetonitrile-water as mobile phase. The column temperature was 30 ℃, injection volume was 1 μL, osthenite was used as the internal standard, electrospray ion source and positive ion mode were used. The m/z values of cyperenone, α-cyperone and osthenite were 219.1/135.1, 219.1/111.0 and 245.0/123.0, respectively. The plasma concentrations of cyperenone and α-cyperone were measured, and the main pharmacokinetic parameters were calculated using DAS 2.0 software. RESULTS The linear relationship of cyperenone was good in the range of 10-500 ng·mL-1(r=0.991 0), and the linear relationship of α-cyperone was good in the range of 2.5-300 ng·mL-1(r=0.994 1), RSDs of intra-day precision were less than 9.45%. RSDs of daytime precision were less than 9.09%. The recoveries were greater than 86.79%. After intragastric administration of essential oil extract(20 mg·kg-1) from Cyperus rotundus L. in SD rats. The pharmacokinetic parameters of Cmax, AUC0-∞ and MRT(0-∞) of cyperenone and α-cyperone were (8 862.59±1 106.81)ng·L-1, (7 060.94±774.25)ng·L-1·h, (3.21±0.72)h and (934.69±106.81)ng·L-1, (792.26±74.52)ng·L-1·h, (4.94± 0.82)h, respectively. CONCLUSION The established method can be used for the rapid and accurate determination of the concentration of cyperenone and α-cyperone in plasma, and can be used for the pharmacokinetic study of cyperenone and α-cyperone in rats in vivo.
4.Analysis of clinical characteristics and prognosis of 235 pancreatic neuroendocrine tumors underwent Sunitinib treatment
Jianming XU ; Heteng CUI ; Ru JIA ; Chuanhua ZHAO ; Ping ZHAO
Chinese Journal of Oncology 2021;43(3):324-328
Objective:To investigate the clinical characteristics, treatment, and prognostic factors of pancreatic neuroendocrine tumors (pNETs) patients treated with Sunitinib.Methods:The clinical data of pNETs patients from Pfizer Drug Assistance Program of Cancer Foundation of China from April 2013 to November 2017 were retrospectively analyzed. Follow-up and statistical analysis were performed.Results:A total of 235 patients were enrolled, the patients′ overall survival time was between 4 and 252 months, the 3-years and 5-years survival rates were 73.8% and 60.8%, respectively. Univariate analysis showed that factors such as age, Ki-67 index and surgery were associated with the 3-years survival rates of pNETs patients ( P<0.05). Multivariate analysis demonstrated that the age, Ki-67 index and surgery were independent prognostic factors for pNETs patients ( P<0.05). For patients with liver metastases, univariate analysis revealed that surgery was associated with prognosis ( P<0.05). The 5-years survival rate of 124 patients with extending usage of Sunitinib was 53.3%. Conclusion:PNETs are rare tumors with atypical clinical symptoms and the patients often have metastasis at the initiate diagnosis. The age, Ki-67 index and surgery are associated with the prognosis of pNETs patients.
5.Analysis of clinical characteristics and prognosis of 235 pancreatic neuroendocrine tumors underwent Sunitinib treatment
Jianming XU ; Heteng CUI ; Ru JIA ; Chuanhua ZHAO ; Ping ZHAO
Chinese Journal of Oncology 2021;43(3):324-328
Objective:To investigate the clinical characteristics, treatment, and prognostic factors of pancreatic neuroendocrine tumors (pNETs) patients treated with Sunitinib.Methods:The clinical data of pNETs patients from Pfizer Drug Assistance Program of Cancer Foundation of China from April 2013 to November 2017 were retrospectively analyzed. Follow-up and statistical analysis were performed.Results:A total of 235 patients were enrolled, the patients′ overall survival time was between 4 and 252 months, the 3-years and 5-years survival rates were 73.8% and 60.8%, respectively. Univariate analysis showed that factors such as age, Ki-67 index and surgery were associated with the 3-years survival rates of pNETs patients ( P<0.05). Multivariate analysis demonstrated that the age, Ki-67 index and surgery were independent prognostic factors for pNETs patients ( P<0.05). For patients with liver metastases, univariate analysis revealed that surgery was associated with prognosis ( P<0.05). The 5-years survival rate of 124 patients with extending usage of Sunitinib was 53.3%. Conclusion:PNETs are rare tumors with atypical clinical symptoms and the patients often have metastasis at the initiate diagnosis. The age, Ki-67 index and surgery are associated with the prognosis of pNETs patients.
6.HD7279's application to the analog electrocardiogram generator controlledby a SCM
Ying FANG ; Qing GUO ; Qing JIAO ; Yongxin GUO ; Chuanhua ZHAO ; Hao ZHENG
Chinese Medical Equipment Journal 1989;0(02):-
This paper introduces the application of H7279intelligent display chip to the selection and display of different kinds of analog electrocardiogram output by the analog electrocardiogram generator controlled by a single chip micyoco(SCM).


Result Analysis
Print
Save
E-mail